Pharmigene, Inc. (TPEX:7595)

Taiwan · Delayed Price · Currency is TWD

8.05

-0.10 (-1.23%)

Nov 6, 2026, 1:54 PM CST

Market Cap	406.24M -18.7%
Revenue (ttm)	187.88M +25.9%
Net Income	-52.27M
EPS	-1.04
Shares Out	50.47M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,210
Open	8.10
Previous Close	8.15
Day's Range	7.41 - 8.10
52-Week Range	5.90 - 11.85
Beta	-0.04
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 12, 2026

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers contract development and manufacturing organization; molecular diagnostic reagents; testing products, including pharmacogenomics, targeted therapy for cancer, disease risk assessment, and functional medicine services. In addition, it sells various platform, such as single-cell analysis platform / spatial gene expression; single-cell and spatial transcriptomics data analysis software; expert in mapping genomic structural variatio... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 2005

Employees 42

Stock Exchange Taipei Exchange

Ticker Symbol 7595

Full Company Profile

Financial Performance

In 2025, Pharmigene's revenue was 199.89 million, an increase of 71.53% compared to the previous year's 116.53 million. Losses were -73.00 million, -11.91% less than in 2024.

Financial Statements